BioTime, Inc. (NYSEAMERICAN:BTX) saw a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 6,899,595 shares, a growth of 0.7% from the November 15th total of 6,852,827 shares. Currently, 5.5% of the company’s shares are sold short. Based on an average daily trading volume, of 286,662 shares, the days-to-cover ratio is presently 24.1 days.

Several research analysts recently issued reports on the stock. BidaskClub upgraded shares of BioTime from a “sell” rating to a “hold” rating in a research note on Thursday, September 28th. Zacks Investment Research downgraded shares of BioTime from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $5.08.

Shares of BioTime (BTX) traded down $0.10 during mid-day trading on Monday, reaching $2.33. 509,300 shares of the company traded hands, compared to its average volume of 353,334. BioTime has a one year low of $2.19 and a one year high of $3.97.

In related news, Director Broadwood Partners, L.P. acquired 2,692,307 shares of the firm’s stock in a transaction on Friday, October 13th. The stock was acquired at an average cost of $2.60 per share, for a total transaction of $6,999,998.20. The purchase was disclosed in a filing with the SEC, which is available at this link.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP boosted its holdings in shares of BioTime by 124.1% during the 3rd quarter. GSA Capital Partners LLP now owns 174,816 shares of the biotechnology company’s stock valued at $496,000 after acquiring an additional 96,816 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of BioTime by 95.6% in the 3rd quarter. Jane Street Group LLC now owns 44,548 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 21,778 shares during the period. Broadwood Capital Inc. lifted its stake in shares of BioTime by 0.6% in the 3rd quarter. Broadwood Capital Inc. now owns 27,279,254 shares of the biotechnology company’s stock worth $77,473,000 after purchasing an additional 160,000 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of BioTime by 29.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 156,721 shares of the biotechnology company’s stock worth $445,000 after purchasing an additional 35,970 shares during the period. Finally, Family Management Corp lifted its stake in shares of BioTime by 29.9% in the 3rd quarter. Family Management Corp now owns 182,350 shares of the biotechnology company’s stock worth $518,000 after purchasing an additional 41,979 shares during the period.

ILLEGAL ACTIVITY NOTICE: “BioTime, Inc. (BTX) Short Interest Up 0.7% in November” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/11/biotime-inc-btx-short-interest-up-0-7-in-november.html.

BioTime Company Profile

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with MarketBeat.com's FREE daily email newsletter.